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Abstract
In the populations of Western countries, particular genotypes of the vacuolating cytotoxin gene, vacA (vacA s, signal region variants; vacA
m, middle region variants) of Helicobacter pylori are believed to be risk factors for the development of peptic ulcers and gastric cancer.
However, it was unclear whether these vacA gene variants are associated with the development of gastrointestinal diseases in develop-
ing nations. The relationship between vacA genotypes and H. pylori-related disease development in Latin American and African popula-
tions was investigated using meta-analysis of 2612 patients from Latin America (2285 strains) and 520 patients from Africa (434 strains).
The frequencies of vacA s and m genotypes differed between strains from Latin America (77.2% for s1 and 68.1% for m1) and Africa
(83.9% for s1 and 56.7% for m1). Latin American strains with s1 and m1 genotypes increased the risk of gastric cancer (OR 4.17, 95%
CI 2.49–6.98 for s1, and 3.59, 2.27–5.68 for m1) and peptic ulcers (e.g. 1.73, 1.37–2.20 for s1). African strains with the s1 or m1 geno-
types also increased the risk of peptic ulcers (8.69, 1.16–64.75 for s1) and gastric cancer (10.18, 2.36–43.84 for m1). The cagA-positive
genotype frequently coincided with s1 and m1 genotypes in both populations. Overall, the vacA s and m genotypes were related to gas-
tric cancer and peptic ulcer development and might be useful markers of risk factors for gastrointestinal disease, especially in Latin
America. Further studies will be required to evaluate the effects of vacA genotypes in African populations because of the small sample
number currently available.
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Introduction
The gastric mucosa of approximately 50% of the world’s
population is infected with Helicobacter pylori, and infection
levels exceed 70% of the population in developing areas,
such as Latin America and Africa [1–3]. Helicobacter pylori
infection is closely associated with the occurrence of peptic
ulcers, gastric cancer, and gastric mucosa-associated
lymphoid tissue lymphoma [4–6]. However, there are
geographical regions where the prevalence of H. pylori infec-
tion does not correlate with the incidence of gastric cancer.
For example, in Africa, the incidence of gastric cancer is rela-
tively low despite the high prevalence of H. pylori infection
(the so-called ‘African enigma’) [7]. Moreover, the incidence
of gastric cancer and the associated mortality vary among
Latin American countries, with, for example, mortality rates
of >20/100 000 in Chile and Costa Rica, and rates of
between 10 and 20/100 000 in Argentina, Brazil, Colombia
and Venezuela for men [8]. Mexico and Puerto Rico had
lower rates of <10/100 000 for men, but these rates were
still higher than those in Canada (5.2/100 000) and the USA
(3.7/100 000) [8].
Gastric epithelial cell injury is caused by a vacuolating
cytotoxin encoded by the vacA gene, which induces host cell
vacuolation and eventual cell death [9,10]. The signal (s)
region encodes part of the cytotoxin’s signal peptide and
N-terminus, while the middle (m) region encodes part of the
55-kDa C-terminal subunit [11]. Two versions of the
s-region (s1 and s2) and m-region (m1 and m2) exist, and
this causes differences in the vacuolating activities among
individual H. pylori strains [11]. The vacA s1 and m1 types can
be further subdivided into s1a, s1b and s1c, and m1a, m1b
and m1c, respectively [11,12]. The vacA s2 genotype encodes
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a shorter extension of the N-terminal peptide on the mature
protein, which blocks the vacuolating activity [13].
Conversely, infection with vacA s1 strains has been linked to
gastric inﬂammation and duodenal ulceration with enhanced
cytotoxin activity [11,13]. In general, the vacA s1m1 strains
produce a large amount of toxin with high vacuolating activ-
ity in gastric epithelial cells, s1m2 strains produce moderate
amounts of toxin, and s2m2 strains produce very little or no
toxin [11,13].
Many authors have described the importance of the
vacA s and m genotypes for clinical outcomes in Western
populations [11,14–20]. In contrast, the importance of the
genotypes for clinical outcomes has not been established
in Latin American and African populations. Among previous
TABLE 1. The vacA s and m genotypes reported in the literature included in the meta-analysis of the Latin American
population
Area/country
Authors
(Reference no.) Year Diseases
Patients
(n)
vacA type
Mix
(n)
Not detected
(n)
s
(n)
s1
(n/%)
s2
(n/%)
m
(n)
m1
(n/%)
m2
(n/%)
Mexico Morales-Espinosa R [21] 1999 NUD, PU 20, I 17S 7 258 228
(88.4)
30
(11.6)
258 222
(86.0)
3
(14.0)
Mexico Gonzalez-Valencia G [22] 2000 NUD, PU 90, I 60S 8 134 78
(58.2)
56
(41.8)
132 77
(58.8)
54
(41.2)
Mexico Garza-Gonzalez E [23] 2004 NUD, PU 50 1g 7 42 21
(50.0)
21
(50.0)
42 24
(57.1)
18
(42.9)
Mexico Chihu L [24] 2004 GC 7 0g 0 7 7
(100)
0
(0.0)
7 7
(100)
0
(0.0)
Costa Rica Con SA [25] 2007 NUD, GC 129 7S 0 122 97
(79.5)
25
(20.5)
122 96*
(78.7)
26
(21.3)
Colombia Nogueira C [26] 2001 NA 178 8g 0 170 157
(92.4)
13
(7.6)
170 152
(89.4)
18
(10.6)
Colombia Bravo LE [27] 2002 NA 252 19g 1 232 208
(89.7)
24
(10.3)
232 200
(86.2)
32
(13.8)
Colombia Our data [15,16,28,29] – NUD, PU, GC 227 9s 0 218 172
(78.9)
46
(21.1)
218 152*
(69.7)
66
(30.3)
Brazil Evans DG [30] 1998 NUD, PU, GC 56 0g 0 56 45
(80.4)
11
(19.6)
56 38
(67.9)
18
(32.1)
Brazil Mattar R [31] 2000 PU 40 17g 0 23 21
(91.3)
2
(8.7)
23 19
(82.6)
4
(17.4)
Brazil De Gusmao VR [32] 2000 NUD, PU 65 10g 0 55 40**
(72.7)
15
(27.3)
54 34**
(63.0)
20
(37.0)
Brazil Ashour AA [33] 2002 NUD, PU, GC 82 11g 0 71 59*,**
(83.1)
12
(16.9)
71 57*,**
(80.3)
14
(19.7)
Brazil Gatti LL [34] 2003 NUD, Others 70 9g 0 61 43
(70.5)
18
(29.5)
NA NA NA
Brazil Birito CAA [35] 2003 NUD, PU 61 0g 5 56 43
(76.8)
13
(23.2)
NA NA NA
Brazil Godoy AP [36] 2003 NUD, PU 155 17g 0 138 86**
(62.3)
52
(37.7)
138 41
(29.7)
97
(70.3)
Brazil Ribeiro ML [37] 2003 NUD, PU 165 28g 0 137 94**
(68.6)
43
(31.4)
137 48
(35.0)
89
(65.0)
Brazil Martins LC [38] 2005 NUD, PU 118 4g 0 114 94
(82.5)
20
(17.5)
114 89**
(78.1)
25
(21.9)
Brazil Mattar R [39] 2005 PU 150 11g 71 68 54
(79.4)
14
(20.6)
68 45
(66.2)
23
(33.8)
Brazil Gatti LL [40] 2006 NUD, PU 89 12g 0 77 57
(74.0)
20
(26.0)
77 59
(76.6)
18
(23.4)
Brazil Proenca Modena JL [41] 2007 NUD, PU 99 18s 0 81 61
(75.3)
20
(24.7)
81 52
(64.2)
29
(35.8)
Brazil Our data [16] – NA 16 0s 0 16 8
(50.0)
8
(50.0)
16 6
(37.5)
10
(62.5)
Venezuela Ghose C [42] 2005 NA 121, I 56s 0 65 46
(70.8)
19
(29.2)
84 49
(58.3)
35
(41.7)
Chile Diaz MI [43] 2005 NUD, PU, GC 79 NAs NA 79 72
(91.1)
7
(8.9)
79 72
(91.1)
7
(8.9)
Argentina Catalano M [44] 2001 NUD, PU 100 3g 0 97 62
(63.9)
35
(36.1)
97 55
(56.7)
42
(43.3)
Argentina Leanza AG [45] 2004 NUD, PU 88 2g 0 86 64
(74.4)
22
(25.6)
86 47
(54.7)
39
(45.3)
Multiple van Doorn LJ [17] 1999 NA 105 25g 0 80 75
(93.7)
5
(6.3)
80 67
(83.8)
13
(16.2)
One study by van Doorn LJ [17] included individuals from Brazil, Colombia, Costa Rica, and Peru; however, the separate data from each country could not be obtained, and
were described as ‘multiple’. ‘Mix’ indicates the number of patients infected with two or more different vacA genotypes. ‘NA’ indicates no data associating Helicobacterpylori
disease development and vacA genotypes. ‘g’ indicates the use of gastric biopsy samples, and ‘s’ refers to the use of single colonies. ‘I’ indicates that the study separately
analysed each H. pylori genotype when patients were determined to be infected with multiple vacA genotypes. Because each H. pylori strain was analysed as a different vacA
genotype [18,22,42,47], patient number and vacA genotype number do not match. A paper reported by Morales-Espinosa [21] was deleted from the meta-analysis of the vacA
genotype because there was a possibility of misinterpreting data derived from several mixed strains from the same patients.
GC, gastric cancer; NA, not available; NUD, non-ulcer dyspepsia (gastritis alone without peptic ulcer and gastric cancer); PU, peptic ulcer (gastric ulcer and/or duodenal
ulcer).
*p <0.05 (signiﬁcantly increased risk of gastric cancer development) and **p <0.05 (signiﬁcantly increased risk of peptic ulcer development).
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studies investigating vacA genotypes in these countries
[15–18,21–51], 21 studies have investigated the relationship
between the vacA genotypes and clinical outcomes [18,21–
23,25,30,32–38,40,41,43–47,51], and of these only eight
[18,25,32,33,36–38,51] and ﬁve [18,25,32,33,38] studies
have revealed that the vacA s1 and m1 genotypes are
linked to an increased risk of gastrointestinal diseases,
respectively (Tables 1 and 2). To evaluate whether the
vacA genotypes are indeed associated with gastrointestinal
diseases in African and Latin American countries, the pres-
ent study was designed to do a systematic analysis of a
sufﬁciently large sample to generate statistically meaningful
data.
Materials and Methods
Study selection
Data from previous studies determining the genotypes of the
vacA s- or m-regions in patients infected with H. pylori in
Latin American and African populations were included in this
study. All eligible studies were identiﬁed by searching the
PubMed database for manuscripts written in English and
published before December 2007 using the following search
criteria: ‘vacA’ or ‘vacuolating cytotoxin’ and ‘Helicobacter’ or
‘pylori’ and ‘genotypes’. The references cited in these manu-
scripts were also screened by the same criteria. Abstracts
and manuscripts that did not provide detailed genotype
information were excluded.
We conducted a meta-analysis to explore the possible
association of the vacA genotypes with the risk of developing
gastrointestinal diseases using data from the articles assem-
bled from PubMed along with our data from Colombia.
Altogether, the genotypes of 197 Colombian patients were
included. Furthermore, we re-examined the vacA genotypes
and cagA status of 30 Colombian strains. These strains were
derived from large H. pylori stocks at Baylor College of
Medicine. Since some of the data for Colombian patients
have been used repeatedly in our previous studies
[15,16,28,29], we removed all overlapping data.
The clinical population consisted of patients diagnosed
with gastric cancer, gastric ulcer, duodenal ulcer, or gastritis
alone based on endoscopic and histopathological diagnoses.
Gastritis was deﬁned as histological gastritis with no peptic
ulcer or gastric cancer. Genotyping of the vacA s- and
m-regions, and cagA status, were determined using PCR as
described previously [11,52,53].
The total patient group that was analysed was subdivided
into the Latin America group (Mexico, Costa Rica, Colombia,
Venezuela, Brazil, Chile and Argentine) and the Africa group
(Egypt, Ethiopia, Nigeria and South Africa).
Data analysis
Whenever possible, patients infected with strains of multi-
ple vacA genotypes were excluded from the meta-analysis.
In four papers [18,22,42,47], although the number of
patients infected with strains of multiple vacA genotypes
was reported, we could not separate the data derived
from patients with H. pylori of multiple vacA genotypes
from those of patients with H. pylori with a single vacA
genotype. In these cases, we included the multiple vacA
genotype data in the meta-analysis. Therefore, the total
TABLE 2. The vacA s and m genotypes reported in the literature included in the meta-analysis of the African population
Area/country Authors (Reference no.) Year Diseases
Patients
(n)
vacA type
Mix
(n)
Not detected
(n)
s
(n)
s1
(n/%)
s2
(n/%)
m
(n)
m1
(n/%)
m2
(n/%)
Egypt van Doorn LJ [17] 1999 NA 33 5g 0 28 12
(42.9)
16
(57.1)
28 4
(14.3)
24
(75.7)
Ethiopia Asrat D [46] 2004 NUD, GC 275 17g 58 200 177
(88.5)
23
(11.5)
200 114
(57.0)
86
(43.0)
Nigeria Smith SI [47] 2002 NUD, PU 41, I 1g 0 42 40
(95.2)
2
(4.8)
42 10
(23.8)
32
(76.2)
Nigeria Owen RJ [48] 2004 NA 8 0g 0 8 8
(100)
0
(0.0)
8 7
(87.5)
1
(12.5)
South Africa Kidd M [18,49,50] 1999, 2001 NUD, PU. GC 109, I 0g 6 103 83*,**
(80.6)
20
(19.4)
103 69*,**
(67.0)
34
(33.0)
South Africa Louw JA [51] 2001 NUD, GC 34 0g 0 34 30*
(88.2)
4
(11.8)
34 27
(79.4)
7
(20.6)
South Africa Owen RJ [48] 2004 NA 7 0g 1 6 5
(83.3)
1
(16.7)
6 4
(66.7)
2
(33.3)
South Africa Yamaoka, Y [16] 2002 NA 13s 0s 0 13 11
(84.6)
2
(15.4)
13 11
(84.6)
2
(15.4)
‘Mix’ indicates the number of patients infected with two or more different vacA genotypes. ‘g’ refers to the use of gastric biopsy samples, and ‘s’ refers to the use of single
colonies. When analysing the prevalence of vacA s and m genotypes, we deleted a number of strains with mixed or undetected genotypes. Because most of the three South
African studies reported by Kidd et al. [18,49,50] contained overlapping data sets, we selected data from [49] for analysis of the prevalence of vacA s and m genotypes.
Abbreviations: see Table 1.
*p <0.05 (signiﬁcant increased risk of gastric cancer development) and **p <0.05 (signiﬁcant increased risk of peptic ulcer development).
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number of patients in the study did not equal the total
number of strains analysed. We also excluded patients
infected with strains of undetected vacA genotypes. When
only one of the s or m genotypes was reported (e.g. s1,
with the m genotype unknown), we included the known
genotype in the meta-analysis. Therefore, in some cases
the total number of s genotypes was not equal to the
number of m genotypes (Table 1). Furthermore, some arti-
cles analysed did not contain the complete vacA genotyping
data [i.e. one or more of vacA s and m genotypes, combi-
nations of s and m genotypes (e.g. s1m1), or s1 subtypes
(s1a, s1b and s1c) were missing]; therefore, the total
numbers were not identical for each genotype, especially
when the data from several different articles were
combined (Tables 1 and 2).
Statistical differences in the prevalence of vacA s and m
genotypes among the individual countries and ethnic groups
were determined by one-way ANOVA or the v2 test. The
effects of vacA s and m genotypes on the risk of gastric
cancer and peptic ulcer were expressed as ORs with 95%
CIs and with reference to subjects with gastritis alone. All
p values were two-sided, and p values <0.05 were consid-
ered statistically signiﬁcant.
Results
Included studies
In addition to the studies conducted in our laboratory, 25
studies from Latin America and eight from Africa were iden-
tiﬁed in PubMed using the above search criteria. However,
one study [21] that investigated 258 H. pylori colonies iso-
lated from only 17 Mexican patients was deleted from the
meta-analysis. The data from South African patients,
reported by Kidd et al. [18,49,50], have been used repeatedly
in three studies, of which we selected one [49] to analyse
the prevalence of the vacA s and m genotypes, along with
another study [18] to analyse the prevalence of the vacA s1
subtypes and their associations with gastroduodenal diseases.
Overall, a total of 24 and eight studies were considered for
meta-analysis concerning populations of Latin America and
Africa, respectively (Tables 1 and 2). We also included our
previous studies of Brazilian and South African patients [16],
and of Colombian patients [15,16,28,29]. Altogether, we
examined 3132 H. pylori-infected patients, including 2612
from Latin America (2285 strains) and 520 from Africa (434
strains) (Tables 1–3).
TABLE 3. Summary of vacA s and m genotypes reported in different countries
Studies
(n)
Patients
(n)
Mix
(n)
Not detected
(n)
s1
(n/%)
s1a
(n/%)
s1b
(n/%)
s1c
(n/%)
vacA type
s2
(n/%)
m1
(n/%)
m2
(n/%)
s1m1
(n/%)
s1m2
(n/%)
s2m1
(n/%)
s2m2
(n/%)
Latin America
Mexico 4 167 78 22 106
(57.9)
21
(21.2)
78
(78.8)
NA 77
(42.1)
108
(75.3)
72
(24.7)
25
(51.0)
3
(6.1)
6
(12.2)
15
(30.6)
Costa Rica 1 129 7 0 97
(79.5)
0
(0)
97
(100)
0
(0)
25
(20.5)
96
(78.7)
26
(21.3)
NA NA NA NA
Brazil 12 1166 137 76 705
(74.0)
20
(6.3)
298
(93.4)
1
(0.3)
248
(26.0)
488
(58.4)
347
(41.6)
475
(57.9)
136
(16.6)
7
(0.9)
202
(24.6)
Colombia 2 657 36 1 537
(86.6)
68
(15.3)
375
(84.5)
1
(0.2)
83
(13.4)
504
(81.3)
116
(18.7)
503
(81.1)
34
(5.5)
0
(0)
83
(13.4)
Venezuela 1 121 56 0 46
(70.8)
0
(0)
32
(69.6)
14
(30.3)
19
(29.2)
49
(58.3)
35
(41.7)
NA NA NA NA
Chile 1 79 NA 0 72
(91.1)
24
(33.3)
48
(66.7)
NA 7
(8.9)
72
(91.1)
7
(8.9)
72
(91.1)
0
(0.0)
0
(0)
7
(8.9)
Argentina 2 188 5 0 126
(68.9)
39
(62.9)
23
(37.1)
0
(0)
57
(31.1)
102
(55.7)
81
(44.3)
101
(55.2)
25
(13.7)
1
(0.5)
56
(30.6)
Others 1 105 25 0 75
(93.8)
0
(0)
74
(98.7)
1
(1.3)
5
(6.2)
67
(83.8)
13
(16.3)
67
(83.8)
8
(10.0)
0
(0)
5
(6.2)
Total 24 2612 344 99 1764*
(77.2)
172
(14.2)
1023
(84.4)
17
(1.4)
521
(22.8)
1486*
(68.1)
697
(31.9)
1243*
(67.8)
206
(11.3)
14
(0.8)
368
(20.1)
Africa
Egypt 1 33 5 0 12
(42.9)
7
(58.3)
5
(41.7)
0
(0)
16
(57.1)
4
(14.3)
24
(85.7)
4
(14.3)
8
(28.6)
0
(0)
16
(57.1)
Ethiopia 1 275 17 58 177
(88.5)
NA NA NA 23
(11.5)
114
(57.0)
86
(23.0)
112
(56.0)
65
(32.5)
2
(1.0)
21
(10.5)
Nigeria 2 49 1 0 48
(96.0)
NA NA NA 2
(4.0)
17
(34.0)
33
(66.0)
17
(34.0)
31
(64.0)
0
(0)
2
(4.0)
South Africa 3 163 0 7 129
(80.9)
1
(1.7)
57
(98.3)
0
(0)
27
(19.7)
111
(70.2)
45
(29.8)
70
(63.7)
18
(16.1)
3
(3.6)
18
(16.7)
Total 6 520 23 65 366*
(83.9)
8
(11.4)
62
(88.6)
0
(0)
68
(16.1)
246*
(56.7)
188
(43.3)
203*
(52.5)
122
(31.5)
5
(1.3)
57
(14.7)
‘Mix’ indicates the number of patients infected with two or more different vacA genotypes. Owen et al. [48] published the data from the Nigeria and South Africa populations.
When patients were found to be infected with multiple Helicobacter pylori strains, each H. pylori strain was analysed separately [18,22,42,47]. Therefore, patient number and
vacA type number do not match. Moreover, because each study measured a different set of parameters (vacA s and m genotypes), as summarized in Tables 1 and 2, the com-
bined numbers of vacA s and m genotypes and s1 subtypes vary for individual countries.
*p <0.05 (signiﬁcant differences of vacA genotypes among different Latin American or African countries).
NA, not available.
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Prevalence of vacA s and m genotypes
Although most of the studies from Africa reported a higher
prevalence of the vacA m1 genotype and the vacA s1m1 com-
bination genotype relative to the m2 and s1m2 genotypes
(Tables 2 and 3), the frequencies of the m1 and s1m1 geno-
types were signiﬁcantly lower in African strains than in Latin
American strains. The prevalence of the vacA s and m geno-
types and the vacA s/m combination genotypes also differed
signiﬁcantly among strains from different countries, in both
Latin America and Africa (p <0.001) (Table 3 and Fig. 1). The
vacA s1b subtype was predominant in strains from all Latin
American and African populations with the exception of
those from Argentina and Egypt, where the s1a subtype was
predominant. The vacA s1c subtype was common only in the
Venezuelan strains [21.5% (14/65) of s genotypes in subjects
with single-colony infections, and 30.3% (14/46) of the total
s1 genotypes], particularly in strains from Amerindian people
living in the Amazonian community of Puerto Ayacucho (Pia-
roas and Guajibos tribes) [77.7% (14/18) and 82.4% (14/17)]
[42]. In the Mexican population, the frequency of the vacA
s2m1 genotype was on average 12.2%, which is higher than
what has been previously reported for other Latin American,
African and Western countries (Table 3) [15–17]. The per-
centage of patients infected with multiple vacA genotypes
was very high in Mexico [46.7% (78/167)] and in Venezuela
[46.3% (56/121)] compared with other Latin American coun-
tries (p <0.05) (Table 3) and developed countries previously
studied, e.g. France and Italy (8.8%) [17] and the Netherlands
(10.6%) [54].
Risk of gastric cancer and peptic ulcer development
associated with the vacA s and m genotypes
The vacA s1 genotype was linked to an increased risk of gas-
tric cancer in four of the eight (50.0%) studies [25,33,49,51],
and this genotype was also linked to an increased risk of
peptic ulcers in ﬁve of 19 (26.3%) studies [32,33,36,38,49].
Likewise, the m1 genotype was linked to gastric cancer in
three of six (50.0%) studies [25,33,49] and to peptic ulcers
in four of 17 (23.5%) studies [32,33,38,49].
In Latin America, the frequency of the vacA s1 genotypes
and s1m1 combination genotype in strains isolated from pep-
tic ulcer or gastric cancer patients was signiﬁcantly higher
than from those with gastritis alone (Table 4). Indeed, carry-
ing H. pylori with the vacA s1 or s1m1 genotype signiﬁcantly
increased the risk of peptic ulcer or gastric cancer compared
with gastritis alone (Table 5).
In Africa, 100% of patients with gastric cancer carried a
vacA s1 strain and >70% of this group carried strains with
the m1 genotype. The vacA m1 genotype signiﬁcantly
(b)(a)
FIG. 1. The proportions of vacA s and m genotypes in different
Latin American (a) and African (b) populations; the frequencies of
vacA s and m genotypes differed among the individual countries of
Latin America.
TABLE 4. Summary of vacA s and m genotypes in relation to risk of peptic ulcer and gastric cancer
Studies
(n)
Patients
(n)
s1
(n/%)
s1a
(n/%)
s1b
(n/%)
s1c
(n/%)
s2
(n/%)
m1
(n/%)
m2
(n/%)
s1m1
(n/%)
s1m2
(n/%)
s2m1
(n/%)
s2m2
(n/%)
Latin America
Gastritis 17 1161 762
(71.3)
67
(13.3)
436
(86.5)
1
(0.2)
305
(28.7)
634
(64.2)
354
(35.8)
479
(60.2)
81
(10.1)
7
(0.9)
229
(28.8)
Peptic ulcer 16 764 528*
(81.2)
55
(19.5)
227
(80.5)
0
(0)
122
(18.8)
404*
(65.5)
213
(34.5)
359*
(65.9)
100
(18.3)
1
(0.2)
85
(15.6)
Gastric cancer 5 169 177*
(91.2)
24
(25.8)
68
(73.1)
1
(1.1)
17
(8.8)
148*
(86.5)
23
(13.5)
124*
(84.9)
6
(4.1)
0
(0)
16
(11.0)
Africa
Gastritis 4 341 234
(85.4)
1
(4.3)
22
(95.6)
NA 40
(14.6)
151
(57.9)
123
(42.1)
112
(56.0)
65
(32.5)
2
(1.0)
21
(10.5)
Peptic ulcer 3 30 33
(97.1)
0
(0)
14
(100)
NA 1
(2.9)
15
(44.1)
19
(55.9)
5
(25.0)
14
(70.0)
0
(0)
1
(5.0)
Gastric cancer 3 25 27
(100)
0
(0)
10
(100)
NA 0
(0)
25*
(92.6)
2
(7.4)
NA NA NA NA
When patients were found to be infected with multiple vacA genotypes, each Helicobacter pylori strain was analysed separately [18,22,42,47]. Therefore, patient number and
genotype number do not match. Moreover, because each study measured a different set of parameters (vacA s and m genotypes), the combined numbers of vacA s and m
genotypes and s1 subtypes vary for individual countries.
NA, not available.
*p <0.05 (vs. signiﬁcant prevalence rate of gastritis patients).
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increased the risk of gastric cancer compared with gastritis
alone (OR 10.18) (Table 5). The vacA s1 genotype also signif-
icantly increased the risk of peptic ulcer (OR 8.69). How-
ever, because the vacA s2 genotype in gastric cancer patients
was absent, we could not analyse the association of vacA s
and s/m combined genotypes with gastrointestinal diseases.
The association of cagA status and vacA genotypes
The cagA status was strongly associated with the vacA s1 and
m1 genotypes (p <0.01) (Table 6). Although there were no sig-
niﬁcant differences in the frequencies of the vacA s genotypes
between the Latin American and African populations, the prev-
alence of the vacA m1 (63.2%) genotype and s1m1 (62.1%)
genotype in cagA-positive patients was lower in Africa than in
Latin America (89.1% and 87.7%, respectively) (p <0.01).
Discussion
Recently, several studies have consistently shown that the
vacA genotype is associated with disease in patients from
various countries [18–20,25,32,33,36,38,49,51]. However,
most of the articles investigating H. pylori strains from Latin
America and Africa have shown no signiﬁcant relationship
between vacA genotypes and gastrointestinal diseases
(Table 1). Due to an insufﬁcient amount of data from each
individual country in Africa and Latin America, researchers
have not been able to draw statistically signiﬁcant conclu-
sions. Using meta-analysis, we were able to demonstrate that
the vacA s1 and m1 genotypes do indeed increase the risk of
gastric cancer and peptic ulcer two- to ﬁve-times in the pop-
ulations of these countries. Therefore, we could conclude
that the H. pylori virulence factor vacA causes enhanced
gastric mucosal inﬂammation and damage, leading to gastric
cancer progression in Latin America, as it does in developed
Western countries. In contrast, only ten studies in Africa,
including three studies reported by Kidd et al., have investi-
gated the association of the vacA genotype with gastrointesti-
nal diseases, and none of the gastric cancer patients in these
studies carried the vacA s2 genotype. This precludes the
analysis of the potential association of the vacA genotypes
with gastrointestinal diseases in African populations.
Helicobacter pylori isolates from some Latin American pop-
ulations were predominantly of the vacA s1b subtype. This
vacA s1b variant is also more frequent in strains obtained
from patients from Portugal and Spain [17,26], two countries
that historically had close cultural and economic ties with
Latin America. Interestingly, there was a high frequency of
the vacA s1c genotype in the Amerindian population of
Puerto Ayacucho, Venezuela [42]. We have previously
reported that 22% of the strains isolated from Native
Colombians had vacA genotypes similar to vacA s1c [16].
These data clearly illustrate a cross link between Native
American and East Asian populations, and conﬁrm that
H. pylori accompanied humans when they crossed the Bering
Strait from Asia to the New World [16].
Gastric cancer is uncommon in Africa, despite high levels
of H. pylori infection (the so-called ‘African enigma’) [7].
South African strains with the vacA s1b subtype produce
VacA protein with low vacuolating activity on cultured epi-
TABLE 5. The risk of gastrointestinal disease development
in relation to Helicobacter pylori virulence factors in Latin
America and Africa
Diseases Factor OR 95% CI p-value
Latin America Peptic ulcer s1 1.73 1.37–2.20 <0.01
m1 1.06 0.86–1.31 0.59
s1m1 2.02 1.52–2.68 <0.01
s1m2 3.27 2.26–4.89 <0.01
Gastric cancer s1 4.17 2.49–6.98 <0.01
m1 3.59 2.27–5.68 <0.01
s1m1 3.71 2.15–6.38 <0.01
s1m2 1.06 0.40–2.80 0.91
Africa Peptic ulcer s1 8.69 1.16–64.75 0.04
m1 0.64 0.31–1.32 0.23
s1m1 0.94 0.56–8.44 0.95
s1m2 4.52 0.56–36.49 0.16
Gastric cancer s1 – – –
m1 10.18 2.36–43.84 <0.01
s1m1 – – –
s1m2 – – –
Due to the absence of the vacA s2 allele in gastric cancer patients from the Afri-
can population, the association of vacA s and s/m combined genotypes with gas-
trointestinal disease could not be analysed.
TABLE 6. The association of cagA status with vacA genotypes
Area cagA status
s1
(n/%)
s2
(n/%)
m1
(n/%)
m2
(n/%)
s1m1
(n/%)
s1m2
(n/%)
s2m1
(n/%)
s2m2
(n/%)
Latin America Positive 822
(95.2)
41
(4.8)
614
(89.1)
75
(10.9)
539
(87.7)
51
(8.3)
7
(1.1)
18
(2.9)
Negative 71
(29.1)
173
(70.9)
47
(22.9)
158
(77.1)
36
(19.8)
15
(8.2)
6
(3.3)
125
(68.7)
Africa Positive 205
(91.9)
18
(8.1)
110*
(63.2)
64*
(36.8)
108*
(62.1)
53*
(30.5)
2
(1.1)
11
(6.3)
Negative 26*
(42.6)
35*
(57.4)
5
(18.5)
22
(81.5)
5
(18.5)
12
(44.4)
0
(0.0)
10
(37.0)
*p <0.05 (vs. Latin American area).
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thelial cells. Moreover, the cagA-positive status coincides less
frequently with the toxic vacA s1m1 genotype in African
H. pylori strains than in strains isolated from Latin America. It
is tempting to speculate that the widespread prevalence of
weakly cytotoxic strains (e.g. s1b) may be the reason for the
low frequency of H. pylori-associated diseases in African pop-
ulations. However, the vacA m1 genotype was predominant
in African strains and signiﬁcantly increased the risk of dis-
ease development in African gastric cancer patients. There-
fore, although gastric carcinogenesis might be inﬂuenced by
the vacA genotypes, the host’s genetic factors, environmental
factors, and other virulence factors of H. pylori should also
be important in determining the risk of gastric cancer.
In conclusion, we have shown that the vacA s1 and m1
genotypes increase the risk of developing gastric cancer and
peptic ulcers, particularly in the Latin American population,
and that the prevalence of speciﬁc vacA s and m genotypes
varies signiﬁcantly among the individual countries of the Afri-
can and South American continents. Genotype testing of
vacA s- and m- regions will be useful in screening individuals
for risk factors for gastric cancer and peptic ulcer develop-
ment, not only in Western countries, but in Latin American
countries as well.
In contrast, there are currently insufﬁcient data to evalu-
ate the effect of the vacA genotypes in H. pylori-related dis-
eases in African populations. The clinical usefulness of vacA
genotyping must be evaluated in future studies of appropriate
design using many individuals and several vacA genotypes
from Africa.
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